NCCR TransCure (2010–2022)

NCCR Directors: Matthias Hediger (2010–2014), Hugues Abriel (2015–2022)

​Home institution: University of Berne

Research of the NCCR

The NCCR “TransCure – From Transport Physiology to Identification of Therapeutic Targets” combined the disciplines of physiology, structural biology and chemistry to develop new therapeutic strategies for treating diseases linked to malfunctions of proteins that are involved in transporting molecules in the human body. These diseases include diabetes, high blood pressure, osteoporosis, heart diseases and certain types of cancer. By broadening scientific knowledge of how transport proteins work, the NCCR applied a fundamental research approach but kept a disease-oriented perspective.

Scientific impact

The integration of leading researchers from the three disciplines into a single entity has proven particularly successful and led to ground-breaking results in the structural and mechanistic understanding of numerous transport proteins. The NCCR gained attention as an internationally leading consortium that positioned Swiss research as a major actor in membrane transport biology, the subfield of biology concerned with cellular transport proteins. In particular, the Institute of Biochemistry and Molecular Medicine at the University of Bern, the NCCR’s home institution, has gained international visibility for membrane biology in Switzerland.

Legacy

During its lifetime, the NCCR continuously examined the translational potential of its ongoing projects, which ultimately led to the founding of the start-up company Synendos Therapeutics. In addition, the NCCR TransCure contributed to the development of key infrastructure, for instance by creating the Screening, Profiling and Analytical Facility (SPAF), which provides valuable services for preclinical drug development. To continuously support their scientific communities, the two NCCRs TransCure and Kidney.CH joined forces to establish the new “Ion Channels and Membrane Transporters” section of Life Sciences Switzerland (LS2). This initiative is expected to maintain the current TransCure network and provide a basis for new collaborations with research groups outside the NCCR.

  • Funding

    Dropdown Icon

    The SNSF awarded 33.5 million Swiss francs to the NCCR over a duration of 12 years. The table below shows that this amount represents just over 41 percent of the NCCR’s overall expenditures. The remaining funds were either own funds provided by the home institution or the participating groups, or contributions by third parties.

    Financing 2010–2022 (Swiss francs)

    Funding source

    2010-2014

    2014-2018

    ​2018-2022

    Overall

    SNSF grant

    14,042,664

    11,587,163

    7,916,809

    33,546,636

    Funds from the home institution

    4,590,667

    4,349,751

    4,674,747

    13,615,165

    Group funds of the project participants

    12,705,603

    11,308,915

    8,685,452

    32,699,970

    External funds

    0

    656,305

    568,706

    1,225,011

    Total

    31,338,934

    27,902,134

    21,845,713

    81,086,782

    Source: SNSF data